A 03

FYI-0401-1407 46308

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

National Institutes of Health
National Institute of
Environmental Health Sciences
P. O. Box 12233
Research Triangle Park, NC 27709

April 02, 2001

Document Control Office (7407)
Attn: TSCA Section FYI
Room G99 East Tower, US EPA
Ofc. of Pollution Prevention & Toxics
401 M St., SW
Washington, DC 20460-0001

RECEIVED
OPPT CBIC
2001 APR -6 AM 7:10

Dear Document Control Office:

In compliance with the National Toxicology Program's (NTP) mission to keep our colleagues informed of the current NTP findings during ongoing studies. We are sending you a copy of the 26-week studies on Pentaerythritol Triacrylate (3524-68-3) and Trimethylolpropane Triacrylate (15625-89-5), the in-life skin papilloma observations and summary pathology tables for Tg.AC mice, which contain the incidence rates of neoplastic and non-neoplastic lesions data and the statistical analysis of primary tumors data pertaining to the laboratory animals. All study data are subject to an NTP retrospective audit and the interpretation may be modified based on the findings.

These tables along with a wide variety of NTP information are also available in electronic format on the world-wide web. For example, the NTP Annual Plan, abstracts of NTP Reports, study data, and the status of all NTP studies may be viewed electronically with access to the internet and a Web browser such as Netscape Navigator or Internet Explorer.

To locate the NTP home page, use the URL http://ntp-server.niehs.nih.gov/. The NTP individual animal and summary pathology tables, survival tables, and survival and growth curves may be accessed from the NTP homepage selecting "Testing Information and Study Results" and then choosing "Data of Completed Studies". Comments on the usefulness of this site and suggestions for improvement are encouraged.

Please contact Central Data Management (CDM) at (919)541-3419 if you have any questions. You may also fax your requests for information to CDM at (919)541-3687 or send them via e-mail to cdm@niehs.nih.gov.

RECEIVED
OPPT NCIC
2001 APR 10 AM 8:49

FYI-01-001407

Contain NO CBI

84010000016

APR 10 AM 8:49

Hard copies of documents such as NTP Technical Reports, short-term Toxicity Reports, and the Report on Carcinogens are available from the Environmental Health Information Service (EHIS). You can contact EHIS by phone at (919) 541-3841, by fax at (919) 541-0273, or by email at ehis@niehs.nih.gov.

Sincerely,

William Eastin

William Eastin, Ph.D.
Head, Information Systems & Central Files
Environmental Toxicology Program

Encls: Pathology Summary Tables for Tg.AC
cc: Central Data Management

NATIONAL TOXICOLOGY PROGRAM

26-Week Subchronic Study in Hemizygous Tg.AC Mice Administered by Dermal Application.

Pentaerythritol Triacrylate (PETA)
(CAS No. 3524-68-3)

Pathology Tables - Tg.AC Mice

E43 - Animals with Skin Papillomas at SOA by Week-on-Dose

P03 - Incidence Rates of Non-Neoplastic Lesions

P05 - Incidence Rates of Neoplasms by Anatomic Site (systemic lesions abridged)

P08 - Statistical Analysis of Primary Tumors

Trimethylolpropane Triacrylate (TMPTA)
(CAS No. 15625-89-5)

Pathology Tables - Tg.AC Mice

E43 - Animals with Skin Papillomas at SOA by Week-on-Dose

P03 - Incidence Rates of Non-Neoplastic Lesions

P05 - Incidence Rates of Neoplasms by Anatomic Site (systemic lesions abridged)

P08 - Statistical Analysis of Primary Tumors

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE

DATE: 04/02/01
TIME: 08:38:15

EIS REPORT 43

FACILITY: Battelle Columbus Laboratory

NTP C#: 88127B

CONTRACT NUMBER: N01-ES-65406

CAS NUMBER: 3524-68-3

ANIMAL SUPPLIER: TACONIC FARMS

CAGE RANGE: ALL

DATE RANGE: ALL

REASONS FOR REMOVAL: ALL

REMOVAL DATE RANGE: ALL

TREATMENT GROUPS: INCLUDE ALL

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 2
TRT: 0 MG/KG

FIRST DOSE: 07/20/98
LAST OBS:

THERE WERE NO PAPILLOMA OBSERVATIONS FOR THIS SPECIES, STRAIN, SEX, AND TREATMENT GROUP

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 4
TRT: 0.75 MG/KG

FIRST DOSE: 07/20/98
LAST OBS:

THERE WERE NO PAPILLOMA OBSERVATIONS FOR THIS SPECIES, STRAIN, SEX, AND TREATMENT GROUP

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 6
TRT: 1.5 MG/KG

FIRST DOSE: 07/20/98
LAST OBS:

THERE WERE NO PAPILLOMA OBSERVATIONS FOR THIS SPECIES, STRAIN, SEX, AND TREATMENT GROUP

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 8
TRT: 3 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		17	18	19	20	21	22	23	24	25	26	27
CAGE	ANIMAL											
0136	136										1	R
0137	137					1	1	1	1	3	3	3
0139	139	1	1	1								
0140	140								1		1	1
0141	141					2	2	4	5	7	7	8
0143	143		1	1	3	3	5	5	5	4	6	4
0144	144								2	2	5	5
0145	145						2	3	4	4	4	4
0148	148						1	1	1	1	1	1
SURVIVORS		15	15	15	15	15	15	15	15	14	14	12
NO. W/TUMORS		1	2	2	1	3	5	5	7	6	8	7
TOTAL TUMORS		1	2	2	3	6	11	14	19	21	28	26
MEAN/SURVIVOR		0.1	0.1	0.1	0.2	0.4	0.7	0.9	1.3	1.5	2.0	2.2
MEAN W/TUMORS		1.0	1.0	1.0	3.0	2.0	2.2	2.8	2.7	3.5	3.5	3.7

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

PAGE: 6
DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 10
TRT: 6 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26
CAGE	ANIMAL																
0151	151		1		K												
0154	154			4	4	6	8	7	10	13	14	15	20	20	20	20	22
0155	155		1	1	5	7	7	10	12	13	14	20	20	20	20	20	20
0156	156									8	9	10	11	12	14	14	17
0157	157					6	5	10	20	18	20	20	20	20	20	20	20
0158	158							12	20	20	22	20	20	21	21	20	29
0159	159	1	1	3	4	4	6	20	20	20	20	20	20	20	20	20	20
0160	160		2	2	2	8	7	15	13	10	20	20	20	20	20	20	20
0161	161				7	9	12	15	17	20	20	20	20	20	20	20	20
0162	162			2	2	4	4	7	8	17	20	20	20	20	20	20	20
0163	163		8	10	10	10	14	20	20	20	20	20	20	20	20	20	20
0164	164				1	2	6	6	20	17	20	20	20	20	20	20	20
0165	165	3	5	5	7	9	8	9	11	13	13	15	13	20	20	20	20
SURVIVORS		15	15	15	14	14	14	14	14	14	14	14	14	14	14	14	14
NO. W/TUMORS		2	6	7	9	10	10	11	11	12	12	12	12	12	12	12	12
TOTAL TUMORS		4	18	27	42	67	77	131	171	189	212	220	224	233	235	234	248
MEAN/SURVIVOR		0.3	1.2	1.8	3.0	4.8	5.5	9.4	12.2	13.5	15.1	15.7	16.0	16.6	16.8	16.7	17.7
MEAN W/TUMORS		2.0	3.0	3.9	4.7	6.7	7.7	11.9	15.5	15.8	17.7	18.3	18.7	19.4	19.6	19.5	20.7

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

PAGE: 7
DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 10
TRT: 6 MG/KG

FIRST DOSE: 07/20/98
LAST CBS: 01/18/99

WEEK-ON-DOSE: 27

CAGE	ANIMAL	
0151	151	
0154	154	20
0155	155	20
0156	156	16
0157	157	R
0158	158	28
0159	159	20
0160	160	20
0161	161	20
0162	162	20
0163	163	20
0164	164	20
0165	165	20

SURVIVORS	13
NO. W/TUMORS	11
TOTAL TUMORS	224
MEAN/SURVIVOR	17.2
MEAN W/TUMORS	20.4

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON.26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

PAGE: 8
DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEM
SEX: FEMALE

TRT#: 12
TRT: 12 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
CAGE	ANIMAL																
0166	166		5	4	5	6	10	13	13	17	20	20	20	R			
0167	167				9	12	12	15	20	20	20	20	20	20	20	20	20
0168	168				6	5	10	17	16	20	20	20	20	20	20	20	20
0169	169				13	15	15	R									
0170	170				10	11	15	15	20		R						
0172	172			3	10	10	13	18	20	20	20	20	20	20	20	20	20
0173	173		3	4	6	8	8	13	15	20	20	20	20	20	20	20	
0174	174		2	3	4	5	6	11	10	15	20	20	21	20	20	20	20
0176	176	4	5	5	6	4	10	11	9	9	14	R					
0177	177			2	5	8	8	15	17	20	20	20	20	20	20	20	20
0178	178		5	6	8	9	9	11	13	13	20	20	20	20	20	20	20
0179	179	1	3	4	4	4	5	5	5	5	6	6	10	9	20	15	20
0180	180			5	11	10	13	20	20	20	20	20	20	20	20	20	20
SURVIVORS		14	14	14	14	14	14	13	13	13	12	11	11	10	10	10	10
NO. W/TUMORS		2	6	9	13	13	13	12	12	11	11	10	10	9	9	9	8
TOTAL TUMORS		5	23	36	97	107	134	164	178	179	200	186	191	169	180	175	160
MEAN/SURVIVOR		0.4	1.6	2.6	6.9	7.6	9.6	12.6	13.7	13.8	16.7	16.9	17.4	16.9	18.0	17.5	16.0
MEAN W/TUMORS		2.5	3.8	4.0	7.5	8.2	10.3	13.7	14.8	16.3	18.2	18.6	19.1	18.8	20.0	19.4	20.0

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:36:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: FEMALE

TRT#: 12
TRT: 12 MG/KG

FIRST DOSE: 07/20/99
LAST OBS: 01/18/99

WEEK-ON-DOSE:		25	26	27
CAGE	ANIMAL			
0166	166			
0167	167	20	20	20
0168	168	20	20	20
0169	169			
0170	170			
0172	172	20	20	20
0173	173	R		
0174	174	20	20	20
0176	176			
0177	177	20	20	20
0178	178	20	20	20
0179	179	17	20	20
0180	180	20	20	21
SURVIVORS		9	9	9
NO. W/TUMORS		8	8	8
TOTAL TUMORS		157	160	161
MEAN/SURVIVOR		17.4	17.8	17.9
MEAN W/TUMORS		19.6	20.0	20.1

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 1
TRT: 0 MG/KG

FIRST DOSE: 07/20/98
LAST OBS:

THERE WERE NO PAPILLOMA OBSERVATIONS FOR THIS SPECIES, STRAIN, SEX, AND TREATMENT GROUP

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 3
TRT: 0.75 MG/KG

FIRST DOSE: 07/20/98
LAST OBS:

THERE WERE NO PAPILLOMA OBSERVATIONS FOR THIS SPECIES, STRAIN, SEX, AND TREATMENT GROUP

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 5
TRT: 1.5 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		20	21	22	23	24	25	26	27
CAGE	ANIMAL								
0032	32		1						
0039	39	1	1	1	1	1	1	1	1
SURVIVORS		15	15	15	15	15	15	15	15
NO. W/TUMORS		1	2	1	1	1		1	1
TOTAL TUMORS		1	2	1	1	1		1	1
MEAN/SURVIVOR		0.1	0.1	0.1	0.1	0.1	[illegible]	0.1	0.1
MEAN W/TUMORS		1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 7
TRT: 3 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		14	15	16	17	18	19	20	21	22	23	24	25	26	27
CAGE	ANIMAL														
0046	46												2	2	2
0048	48							1	2	2	2	1	2	3	3
0049	49							4	5	6	6	7	6	8	7
0050	50								2	9	9	11	11	12	10
0051	51									3	3	4	4	3	6
0052	52													1	1
0053	53		1	2	1	1									
0054	54								3	3	2	5	5	5	5
0056	56					4	3	3	2	3	4	5	9	10	11
0057	57	1	1	2	2	2	2	2	4	4	5	8	7	9	11
0058	58			3	2	2	2	2	1	1	1	1	1	1	2
0059	59			1	1	1	1	1	1	1	1	1	2	3	3
0060	60						1	1	1	1	1	1	1	1	1
SURVIVORS		15	15	15	15	15	15	15	15	15	15	15	15	15	15
NO. W/TUMORS		1	2	4	4	5	5	7	9	10	10	10	11	12	12
TOTAL TUMORS		1	2	8	6	10	9	14	21	33	34	44	50	58	62
MEAN/SURVIVOR		0.1	0.1	0.5	0.4	0.7	0.6	0.9	1.4	2.2	2.3	2.9	3.3	3.9	4.1
MEAN W/TUMORS		1.0	1.0	2.0	1.5	2.0	1.8	2.0	2.3	3.3	3.4	4.4	4.5	4.8	5.2

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 9
TRT: 6 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
CAGE	ANIMAL																
0061	61	2	2	2	2	6	6	7	9	17	21	20	20	20	20	20	20
0062	62					3	3	3	3	3	5	5	6	6	8	15	20
0063	63			2	2	3	5	6	7	13	15	16	20	20	20	20	20
0064	64				2	2	6	7	7	9	11	13	17	15	20	20	20
0065	65				4	5	3	3	4	6	13	14	14	18	17	22	20
0066	66						2	3	4	8	10	15	17	20	20	20	20
0067	67							5	6	9	9	11	12	16	20	20	20
0068	68					2	2	2	3	6	6	7	11	11	12	15	20
0069	69						3	2	3	2	5	5	4	4	10	13	16
0070	70				2	4	7	9	7	12	15	20	20	22	20	20	20
0071	71		1	1	1	1	1	2	4	3	5	6	12	12	15	14	20
0072	72					2	3	5	8	6	16	20	20	20	20	23	23
0073	73					1	4	4	5	5	6	5	9	14	15	14	20
0074	74						4	7	4	10	11	13	11	15	20	20	20
0075	75							5	8	10	20	18	20	20	20	20	20
SURVIVORS		15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15
NO. W/TUMORS		1	2	3	6	10	13	15	15	15	15	15	15	15	15	15	15
TOTAL TUMORS		2	3	5	13	29	49	70	82	119	168	188	213	233	257	276	299
MEAN/SURVIVOR		0.1	0.2	0.3	0.9	1.9	3.3	4.7	5.5	7.9	11.2	12.5	14.2	15.5	17.1	18.4	19.9
MEAN W/TUMORS		2.0	1.5	1.7	2.2	2.9	3.8	4.7	5.5	7.9	11.2	12.5	14.2	15.5	17.1	18.4	19.9

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 9
TRT: 6 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		25	26	27
CAGE	ANIMAL			
0061	61	R		
0062	62	20	20	20
0063	63	R		
0064	64	20	20	20
0065	65	20	20	20
0066	66	20	20	20
0067	67	20	20	20
0068	68	17	23	22
0069	69	17	21	21
0070	70	20	20	20
0071	71	20	20	20
0072	72	20	25	25
0073	73	15	20	20
0074	74	20	20	20
0075	75	20	20	20
SURVIVORS		13	13	13
NO. W/TUMORS		13	13	13
TOTAL TUMORS		249	269	268
MEAN/SURVIVOR		19.2	20.7	20.6
MEAN W/TUMORS		19.2	20.7	20.6

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EISRPT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 11
TRT: 12 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
CAGE	ANIMAL																
0076	76	4	4	4	6	7	7	11	10	18	21	22	22	26	21	20	20
0077	77					7	10	12	13	15	20	22	25	24	24	25	24
0079	79		2	4	9	10	11	20	20	18	22	23	24	25	21	21	21
0080	80		3	6	10	11	12	20	16	20	20	20	20	20	20	20	20
0081	81	3	5	4	10	14	9	10	15	20	20	20	20	20	20	20	20
0083	83			3	4	6	6	6	6	7	12	15	15	20	20	20	20
0084	84	4	8	9	14	14	14	15	16	20	20	20	20	20	20	20	20
0085	85	4	13	15	20	20	20	20	20	24	23	24	24	23	23	23	22
0086	86	1	1	1	4	5	4	4	6	10	17	12	15	20	20	20	22
0087	87	2	2	2	2	2	2	3	3	4	4	7	12	14	20	20	20
0088	88			3	7	6	7	13	16	20	20	20	20	R			
0089	89		8	10	15	20	20	20	20	20	20	20	20	20	20	20	20
0090	90				13	20	20	20	20	20	20	24	25	24	24	23	R
SURVIVORS		15	15	15	15	15	15	15	15	15	15	15	15	14	14	14	13
NO. W/TUMORS		6	9	11	12	13	13	13	13	13	13	13	13	12	12	12	11
TOTAL TUMORS		18	46	61	114	142	142	174	181	216	239	249	262	256	253	252	229
MEAN/SURVIVOR		1.2	3.1	4.1	7.6	9.5	9.5	11.6	12.1	14.4	15.9	16.6	17.5	18.3	18.1	18.0	17.6
MEAN W/TUMORS		3.0	5.1	5.5	9.5	10.9	10.9	13.4	13.9	16.6	18.4	19.2	20.2	21.3	21.1	21.0	20.8

NTP EXP/TEST: 88127-06
TEST TYPE: SUBCHRON 26-WEEK
ROUTE: SKIN APPLICATION

PENTAERYTHRITOL TRIACRYLATE (PETA)
ANIMALS WITH SKIN PAPILLOMAS AT SOA BY WEEK-ON-DOSE
EIS.PT43

DATE: 04/02/01
TIME: 08:38:15

SPECIES-STRAIN: MICE-TG.AC HEMI
SEX: MALE

TRT#: 11
TRT: 12 MG/KG

FIRST DOSE: 07/20/98
LAST OBS: 01/18/99

WEEK-ON-DOSE:		25	26	27
CAGE	ANIMAL			
0076	76	20	20	20
0077	77	24	24	24
0079	79	24	28	R
0080	80	20	20	20
0081	81	20	20	20
0083	83	20	20	20
0084	84	20	20	20
0085	85	22	23	23
0086	86	20	22	22
0087	87	20	R	
0088	88			
0089	89	R		
0090	90			
SURVIVORS		12	11	10
NO. W/TUMORS		10	9	8
TOTAL TUMORS		210	197	169
MEAN/SURVIVOR		17.5	17.9	16.9
MEAN W/TUMORS		21.0	21.9	21.1

B 09

----END-OF-REPORT----

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

Facility: Battelle Columbus Laboratory

Chemical CAS #: 3524-68-3

Lock Date: 06/16/99

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
DISPOSITION SUMMARY						
Animals Initially In Study	15	15	15	15	15	15
Early Deaths						
Natural Death	2		3	3	2	3
Moribund Sacrifice	1	1				3
Survivors						
Terminal Sacrifice	12	14	12	12	13	9
Animals Examined Microscopically	15	15	15	15	15	15
ALIMENTARY SYSTEM						
Liver	(15)	(15)	(15)	(15)	(15)	(15)
Hematopoietic Cell Proliferation				1 (7%)	1 (7%)	6 (40%)
Inflammation, Chronic Active	12 (80%)	14 (93%)	11 (73%)	14 (93%)	13 (87%)	11 (73%)
Necrosis						1 (7%)
Pigmentation	11 (73%)	11 (73%)	9 (60%)	13 (87%)	5 (33%)	2 (13%)
Bile Duct, Hyperplasia					1 (7%)	
Hepatocyte, Necrosis	2 (13%)	2 (13%)	2 (13%)	3 (20%)	4 (27%)	2 (13%)
Stomach, Forestomach	(15)	(15)	(15)	(15)	(15)	(15)
Hyperkeratosis	1 (7%)		3 (20%)	3 (20%)	4 (27%)	4 (27%)
Inflammation					2 (13%)	
Epithelium, Hyperplasia	1 (7%)				2 (13%)	
Epithelium, Ulcer					1 (7%)	
Tooth	(4)		(3)	(3)	(1)	
Inflammation, Chronic Active				1 (33%)		
CARDIOVASCULAR SYSTEM						
Heart	(15)	(15)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active		1 (7%)				1 (7%)
ENDOCRINE SYSTEM						
Adrenal Cortex	(15)	(15)	(15)	(15)	(15)	(15)
Hematopoietic Cell Proliferation						1 (7%)
Necrosis						1 (7%)
Capsule, Hyperplasia	1 (7%)	4 (27%)	7 (47%)	2 (13%)	1 (7%)	2 (13%)
Pituitary Gland	(15)	(15)	(14)	(15)	(15)	(15)
Pars Distalis, Cyst	3 (20%)		2 (14%)	2 (13%)	4 (27%)	2 (13%)

a Number of animals examined microscopically at site and number of animals with lesion

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Ovary	(15)	(15)	(15)	(15)	(15)	(15)
Cyst	1 (7%)			1 (7%)	2 (13%)	
Uterus	(15)	(15)	(15)	(15)	(15)	(15)
Hydrometra	1 (7%)					2 (13%)
Endometrium, Hyperplasia, Cystic	11 (73%)	9 (60%)	7 (47%)	10 (67%)	11 (73%)	7 (47%)
HEMATOPOIETIC SYSTEM						
Lymph Node	(15)	(14)	(13)	(12)	(15)	(14)
Hematopoietic Cell Proliferation						2 (14%)
Inguinal, Hematopoietic Cell Proliferation						1 (7%)
Inguinal, Hyperplasia						1 (7%)
Mediastinal, Hematopoietic Cell Proliferation						1 (7%)
Mediastinal, Hyperplasia						1 (7%)
Mediastinal, Necrosis, Lymphoid			1 (8%)			
Lymph Node, Mandibular	(15)	(15)	(15)	(15)	(15)	(13)
Hematopoietic Cell Proliferation					1 (7%)	8 (62%)
Hyperplasia	3 (20%)		1 (7%)	5 (33%)	3 (20%)	1 (8%)
Necrosis, Lymphoid		1 (7%)	1 (7%)			
Lymph Node, Mesenteric	(14)	(15)	(15)	(14)	(15)	(15)
Necrosis, Lymphoid		1 (7%)				
Spleen	(15)	(15)	(15)	(15)	(15)	(15)
Depletion Cellular	2 (13%)	1 (7%)	2 (13%)	1 (7%)	2 (13%)	3 (20%)
Hematopoietic Cell Proliferation				2 (13%)	11 (73%)	11 (73%)
Necrosis, Lymphoid		1 (7%)	1 (7%)		1 (7%)	
Thymus	(15)	(15)	(15)	(14)	(14)	(15)
Atrophy	3 (20%)		2 (13%)	2 (14%)	3 (21%)	6 (40%)
Pigmentation				1 (7%)		
Thymocyte, Necrosis		1 (7%)	2 (13%)	2 (14%)		5 (33%)
INTEGUMENTARY SYSTEM						
Skin	(15)	(15)	(15)	(15)	(15)	(15)
Epidermis, Skin, Site of Application,						

a Number of animals examined microscopically at site and number of animals with lesion

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
INTEGUMENTARY SYSTEM - CONT						
Hyperplasia			5 (33%)	14 (93%)	14 (93%)	14 (93%)
Epidermis, Skin, Site of Application, Ulcer						1 (7%)
Sebaceous Gland, Skin, Site of Application, Hyperplasia, Adenomatous					1 (7%)	
Skin, Site of Application, Cyst Epithelial Inclusion					1 (7%)	1 (7%)
Skin, Site of Application, Hyperkeratosis	1 (7%)		4 (27%)	14 (93%)	11 (73%)	13 (87%)
Skin, Site of Application, Inflammation, Chronic Active			1 (7%)	9 (60%)	10 (67%)	15 (100%)
Subcutaneous Tissue, Hemorrhage				1 (7%)		
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
Lung	(15)	(15)	(15)	(15)	(15)	(15)
Infiltration Cellular, Mononuclear Cell			1 (7%)			
Inflammation, Chronic Active				1 (7%)		1 (7%)
Alveolar Epithelium, Hyperplasia					1 (7%)	
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(15)	(15)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active	1 (7%)	2 (13%)	1 (7%)	1 (7%)	1 (7%)	1 (7%)
Nephropathy	3 (20%)					2 (13%)
Polyarteritis	1 (7%)					
Cortex, Cyst						2 (13%)
Papilla, Necrosis			1 (7%)			

a Number of animals examined microscopically at site and number of animals with lesion

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
URINARY SYSTEM - CONT						
Renal Tubule, Degeneration						1 (7%)
Renal Tubule, Hyperplasia			1 (7%)	1 (7%)		
Renal Tubule, Necrosis						2 (13%)
Renal Tubule, Regeneration	1 (7%)	1 (7%)		2 (13%)	1 (7%)	

a Number of animals examined microscopically at site and number of animals with lesion

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
DISPOSITION SUMMARY						
Animals Initially In Study	15	15	15	15	15	15
Early Deaths						
Natural Death	3				2	5
Moribund Sacrifice		1			1	
Survivors						
Terminal Sacrifice	12	14	15	15	12	10
Animals Examined Microscopically	15	15	15	15	15	15
ALIMENTARY SYSTEM						
Liver	(15)	(15)	(13)	(15)	(15)	(15)
Atrophy	1 (7%)					
Hematopoietic Cell Proliferation					2 (13%)	
Inflammation, Chronic Active	5 (33%)	11 (73%)	10 (67%)	13 (87%)	13 (87%)	5 (33%)
Mineralization	1 (7%)					
Myelodysplasia						5 (33%)
Pigmentation		1 (7%)	1 (7%)			
Hepatocyte, Necrosis	1 (7%)		1 (7%)		1 (7%)	1 (7%)
Hepatocyte, Vacuolization Cytoplasmic			1 (7%)			
Stomach, Forestomach	(15)	(15)	(15)	(15)	(15)	(15)
Hyperkeratosis	2 (13%)		1 (7%)		3 (20%)	4 (27%)
Epithelium, Hyperplasia			1 (7%)			
CARDIOVASCULAR SYSTEM						
Heart	(15)	(15)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active		3 (20%)			1 (7%)	
Myelodysplasia						3 (20%)
ENDOCRINE SYSTEM						
Adrenal Cortex	(15)	(15)	(15)	(15)	(15)	(15)
Hypertrophy	7 (47%)	10 (67%)	3 (20%)	5 (33%)	1 (7%)	3 (20%)
Myelodysplasia						2 (13%)
Adrenal Medulla	(15)	(15)	(15)	(15)	(15)	(15)
Myelodysplasia						2 (13%)
Pituitary Gland	(15)	(14)	(15)	(15)	(15)	(15)
Pars Distalis, Cyst	1 (7%)				3 (20%)	

a Number of animals examined microscopically at site and number of animals with lesion

MICE:TGAC (PVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
ENDOCRINE SYSTEM - CONT						
Thyroid Gland	(15)	(15)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active					1 (7%)	
Myelodysplasia						1 (7%)
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Epididymis	(15)	(14)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active		1 (7%)				4 (27%)
Myelodysplasia						5 (33%)
Bilateral, Hypospermia						1 (7%)
Unilateral, Hypospermia	1 (7%)	1 (7%)				2 (13%)
Preputial Gland						(1)
Duct, Ectasia						1 (100%)
Testes	(15)	(15)	(15)	(15)	(15)	(15)
Cyst	2 (13%)	1 (7%)		1 (7%)	1 (7%)	
Bilateral, Germinal Epithelium, Degeneration					1 (7%)	
Unilateral, Germinal Epithelium, Degeneration	1 (7%)	1 (7%)		2 (13%)	1 (7%)	4 (27%)
HEMATOPOIETIC SYSTEM						
Lymph Node	(14)	(15)	(14)	(13)	(15)	(15)
Hyperplasia					1 (7%)	1 (7%)
Inflammation, Chronic Active					1 (7%)	
Myelodysplasia						1 (7%)
Inguinal, Myelodysplasia						1 (7%)
Mediastinal, Hyperplasia					1 (7%)	
Mediastinal, Myelodysplasia						1 (7%)
Lymph Node, Mandibular	(15)	(15)	(15)	(15)	(15)	(15)
Hematopoietic Cell Proliferation					3 (20%)	
Hyperplasia			2 (13%)	1 (7%)	2 (13%)	
Hyperplasia, Plasma Cell						1 (7%)
Myelodysplasia						2 (13%)
Necrosis, Lymphoid					2 (13%)	
Lymph Node, Mesenteric	(12)	(15)	(15)	(15)	(15)	(14)
Hematopoietic Cell Proliferation					1 (7%)	1 (7%)
Myelodysplasia						3 (21%)

a Number of animals examined microscopically at site and number of animals with lesion

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
HEMATOPOIETIC SYSTEM - CONT						
Necrosis, Lymphoid					1 (7%)	
Spleen	(15)	(15)	(15)	(15)	(15)	(15)
Atrophy	1 (7%)					
Depletion Cellular					2 (13%)	2 (13%)
Hematopoietic Cell Proliferation	1 (7%)	2 (13%)	1 (7%)	2 (13%)	9 (60%)	6 (40%)
Myelodysplasia						4 (27%)
Necrosis, Lymphoid					2 (13%)	1 (7%)
Thymus	(15)	(15)	(15)	(15)	(14)	(14)
Atrophy	4 (27%)	1 (7%)	2 (13%)		4 (29%)	5 (36%)
Myelodysplasia						3 (21%)
Thymocyte, Necrosis					2 (14%)	
INTEGUMENTARY SYSTEM						
Skin	(15)	(15)	(15)	(15)	(15)	(15)
Dermis, Skin, Site of Application, Necrosis						1 (7%)
Epidermis, Skin, Site of Application, Hyperplasia			3 (20%)	8 (53%)	10 (67%)	14 (93%)
Epidermis, Skin, Site of Application, Ulcer					1 (7%)	
Skin, Site of Application, Cyst Epithelial Inclusion						1 (7%)
Skin, Site of Application, Hyperkeratosis	1 (7%)		2 (13%)	6 (40%)	10 (67%)	13 (87%)
Skin, Site of Application, Inflammation, Chronic Active				2 (13%)	5 (33%)	12 (80%)
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
Lung	(15)	(15)	(15)	(15)	(15)	(15)
Inflammation, Chronic Active					1 (7%)	2 (13%)
Myelodysplasia						3 (20%)
Alveolar Epithelium, Hyperplasia			1 (7%)			

a Number of animals examined microscopically at site and number of animals with lesion

NTP Experiment-Test: 88127-06
Study Type: SUBCHRON 26-WEEK
Route: SKIN APPLICATION

INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

Report: PEIRPT03
Date: 03/30/01
Time: 14:38:37

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(15)	(15)	(15)	(15)	(15)	(15)
Hydronephrosis						1 (7%)
Infarct			1 (7%)	2 (13%)		
Inflammation, Chronic Active	1 (7%)		4 (27%)	4 (27%)	3 (20%)	
Mineraiization					1 (7%)	
Myelodysplasia						4 (27%)
Nephropathy	6 (40%)	1 (7%)				
Pigmentation	1 (7%)					
Cortex, Cyst		1 (7%)		1 (7%)	1 (7%)	1 (7%)
Renal Tubule, Dilatation				1 (7%)		
Renal Tubule, Regeneration	1 (7%)	2 (13%)		3 (20%)		

a Number of animals examined microscopically at site and number of animals with lesion

C 05

END OF REPORT

Facility: Battelle Columbus Laboratory

Chemical CAS #: 3524-68-3

Lock Date: 06/16/99

Cage Range: All

Reasons For Removal: All

Removal Date Range: All

Treatment Groups: Include All

a Number of animals examined microscopically at site and number of animals with lesion

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
DISPOSITION SUMMARY						
Animals Initially in Study	15	15	15	15	15	15
Early Deaths						
Natural Death	2		3	3	2	3
Moribund Sacrifice	1	1				3
Survivors						
Terminal Sacrifice	12	14	12	12	13	9
Animals Examined Microscopically	15	15	15	15	15	15
ALIMENTARY SYSTEM						
Liver	(15)	(15)	(15)	(15)	(15)	(15)
Salivary Glands						(1)
Carcinoma						1 (100%)
Stomach, Forestomach	(15)	(15)	(15)	(15)	(15)	(15)
Squamous Cell Papilloma	2 (13%)	4 (27%)	5 (33%)	4 (27%)	6 (40%)	3 (20%)
Squamous Cell Papilloma, Multiple	3 (20%)			3 (20%)	1 (7%)	1 (7%)
Tooth	(4)		(3)	(3)	(1)	
Odontogenic Tumor	4 (100%)		3 (100%)	2 (67%)	1 (100%)	
CARDIOVASCULAR SYSTEM						
Heart	(15)	(15)	(15)	(15)	(15)	(15)
ENDOCRINE SYSTEM						
Adrenal Cortex	(15)	(15)	(15)	(15)	(15)	(15)
Adrenal Medulla	(15)	(15)	(15)	(14)	(15)	(15)
Pheochromocytoma Benign			1 (7%)			
Pituitary Gland	(15)	(15)	(14)	(15)	(15)	(15)
GENERAL BODY SYSTEM						
None						

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
GENITAL SYSTEM						
Ovary	(15)	(15)	(15)	(15)	(15)	(15)
Uterus	(15)	(15)	(15)	(15)	(15)	(15)
Vagina					(1)	
Squamous Cell Papilloma					1 (100%)	
HEMATOPOIETIC SYSTEM						
Lymph Node	(15)	(14)	(13)	(12)	(15)	(14)
Lymph Node, Mandibular	(15)	(15)	(15)	(15)	(15)	(13)
Lymph Node, Mesenteric	(14)	(15)	(15)	(14)	(15)	(15)
Spleen	(15)	(15)	(15)	(15)	(15)	(15)
Thymus	(15)	(15)	(15)	(14)	(14)	(15)
INTEGUMENTARY SYSTEM						
Skin	(15)	(15)	(15)	(15)	(15)	(15)
Squamous Cell Papilloma, Multiple					1 (7%)	
Skin, Site of Application, Keratoacanthoma						1 (7%)
Skin, Site of Application, Squamous Cell Carcinoma						1 (7%)
Skin, Site of Application, Squamous Cell Papilloma				3 (20%)		
Skin, Site of Application, Squamous Cell Papilloma, Multiple			1 (7%)	7 (47%)	12 (80%)	13 (87%)
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						

INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
PENTAERYTHRITOL TRIACRYLATE (PETA)

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
RESPIRATORY SYSTEM						
Lung	(15)	(15)	(15)	(15)	(15)	(15)
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(15)	(15)	(15)	(15)	(15)	(15)
SYSTEMIC LESIONS						
Multiple Organs	*(15)	*(15)	*(15)	*(15)	*(15)	*(15)
Leukemia Erythrocytic	1 (7%)					1 (7%)
Lymphoma Malignant				1 (7%)		

* Number of animals with any tissue examined microscopically

NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK PENTAERYTHRITOL TRIACRYLATE (PETA) Date: 03/30/01
Route: SKIN APPLICATION Time: 14:38:30

MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
TUMOR SUMMARY						
Total Animals with Primary Neoplasms (b)	9	4	6	13	13	14
Total Primary Neoplasms	10	4	10	20	22	21
Total Animals with Benign Neoplasms	5	4	6	11	13	13
Total Benign Neoplasms	5	4	7	17	21	18
Total Animals with Malignant Neoplasms	1			1		3
Total Malignant Neoplasms	1			1		3
Total Animals with Metastatic Neoplasms						
Total Metastatic Neoplasm						
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain-Benign or Malignant	4		3	2	1	
Total Uncertain Neoplasms	4		3	2	1	

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK PENTAERYTHRITOL TRIACRYLATE (PETA) Date: 03/30/01
Route: SKIN APPLICATION Time: 14:38:30

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
DISPOSITION SUMMARY						
Animals Initially in Study	15	15	15	15	15	15
Early Deaths						
Natural Death	3				2	5
Moribund Sacrifice		1			1	
Survivors						
Terminal Sacrifice	12	14	15	15	12	10
Animals Examined Microscopically	15	15	15	15	15	15
ALIMENTARY SYSTEM						
Liver	(15)	(15)	(15)	(15)	(15)	(15)
Salivary Glands	(1)	(1)		(1)		(1)
Carcinoma	1 (100%)	1 (100%)		1 (100%)		1 (100%)
Stomach, Forestomach	(15)	(15)	(15)	(15)	(15)	(15)
Squamous Cell Papilloma	2 (13%)	3 (20%)	5 (33%)	5 (33%)	5 (33%)	3 (20%)
Squamous Cell Papilloma, Multiple	4 (27%)	1 (7%)		3 (20%)		2 (13%)
Tooth	(2)		(3)	(1)	(3)	(2)
Odontogenic Tumor	2 (100%)		3 (100%)	1 (100%)	3 (100%)	2 (100%)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						
None						

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
GENITAL SYSTEM						
None						
HEMATOPOIETIC SYSTEM						
Spleen	(15)	(15)	(15)	(15)	(15)	(15)
INTEGUMENTARY SYSTEM						
Skin	(15)	(15)	(15)	(15)	(15)	(15)
Squamous Cell Papilloma, Multiple						1 (7%)
Skin, Site of Application, Keratoacanthoma				2 (13%)	2 (13%)	2 (13%)
Skin, Site of Application, Keratoacanthoma, Multiple					1 (7%)	4 (27%)
Skin, Site of Application, Squamous Cell Carcinoma				2 (13%)		2 (13%)
Skin, Site of Application, Squamous Cell Carcinoma, Multiple						1 (7%)
Skin, Site of Application, Squamous Cell Papilloma	1 (7%)		4 (27%)	4 (27%)		
Skin, Site of Application, Squamous Cell Papilloma, Multiple				11 (73%)	15 (100%)	13 (87%)
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
Lung	(15)	(15)	(15)	(15)	(15)	(15)
Alveolar/Bronchiolar Adenoma	2 (13%)	1 (7%)				
Carcinoma, Metastatic, Salivary Glands		1 (7%)				

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
Kidney	(15)	(15)	(15)	(15)	(15)	(15)
SYSTEMIC LESIONS						
Multiple Organs	*(15)	*(15)	*(15)	*(15)	*(15)	*(15)
Leukemia Erythrocytic						1 (7%)

* Number of animals with any tissue examined microscopically

NTP Experiment-Test: 88127-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: SUBCHRON 26-WEEK PENTAERYTHRITOL TRIACRYLATE (PETA) Date: 03/30/01
Route: SKIN APPLICATION Time: 14:38:30

MICE:TGAC (FVB/N) HEMIZYGOUS MALE	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
TUMOR SUMMARY						
Total Animals with Primary Neoplasms (b)	9	5	9	15	15	13
Total Primary Neoplasms	12	6	12	29	26	32
Total Animals with Benign Neoplasms	7	5	8	15	15	13
Total Benign Neoplasms	9	5	9	25	23	25
Total Animals with Malignant Neoplasms	1	1		3		5
Total Malignant Neoplasms	1	1		3		5
Total Animals with Metastatic Neoplasms		1				
Total Metastatic Neoplasm		1				
Total Animals with Malignant Neoplasms Uncertain Primary Site						
Total Animals with Neoplasms Uncertain-Benign or Malignant	2		3	1	3	2
Total Uncertain Neoplasms	2		3	1	3	2

a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors

---------- END OF REPORT ----------

D 01

REASONS FOR REMOVAL: ALL

REMOVAL DATE RANGE: ALL

TREATMENT GROUPS: INCLUDE ALL

NTP
LAB: Battelle Columbus
EXPERIMENT: 88127 TEST: 06
TEST TYPE: SUBCHRON 26-WEEK
CONT: NO1-ES-65406
PATHOLOGIST: TOFT, JOHN
Mice(TG.AC HETEROZYGOUS TRANSGENIC)

STATISTICAL ANALYSIS OF PRIMARY TUMORS
PENTAERYTHRITOL TRIACRYLATE (PETA)

CAGES FROM 0000 TO LAST CAGE
ROUTE: SKIN APPLICATION

REPORT: PEIRPT08
DATE: 03/30/01
TIME: 14:38:29

NTP C#: 88127B
CAS: 3524-68-3

FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED. IN OTHER TISSUES/ORGANS RATES ARE BASED ON THE NUMBER OF ANIMALS NECROPSIED.

Adrenal Medulla
Lung
Salivary Glands

NTP
LAB: Battelle Columbus
EXPERIMENT: 88127 TEST: 06
TEST TYPE: SUBCHRON 26-WEEK
CONT: N01-ES-65406
PATHOLOGIST: TOFT, JOHN

STATISTICAL ANALYSIS OF PRIMARY TUMORS
PENTAERYTHRITOL TRIACRYLATE (PETA)

CAGES FROM 0000 TO LAST CAGE
ROUTE: SKIN APPLICATION

REPORT: PEIRPT08
DATE: 03/30/01
TIME: 14:38:29

NTP C#: 88127B
CAS: 3524-68-3

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF PENTAERYTHRITOL TRIACRYLATE (PETA)

Male Mice

Organ	Morphology
Skin	
Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom	
	Keratoacanthoma
	Squamous Cell Carcinoma
	Squamous Cell Papilloma
	Squamous Cell Papilloma, Papilloma, Squamous Cell Carcinoma or Keratoacanthoma
	Squamous Cell Papilloma, Papilloma, or Keratoacanthoma
All Organs	Benign Tumors
	Malignant Tumors
	Malignant and Benign Tumors

Female Mice

Organ	Morphology
Skin	
Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom	
	Squamous Cell Papilloma
	Squamous Cell Papilloma, Papilloma, Squamous Cell Carcinoma or Keratoacanthoma
	Squamous Cell Papilloma, Papilloma, or Keratoacanthoma
Tooth	Odontogenic Tumor
All Organs	Benign Tumors
	Malignant Tumors
	Malignant and Benign Tumors

Statistical Analysis of Primary Tumors in Mice(TG.AC HETEROZYGOUS TRANSGENIC) - PENTAERYTHRITOL TRIACRYLATE (PETA)

Terminal Sacrifice at 27 weeks

Males

Dose	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
Lung Alveolar/Bronchiolar Adenoma						
TUMOR RATES						
OVERALL (a)	2/15 (13%)	1/15 (7%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)
POLY-3 RATE (b)	2/13.95	1/14.34	0/15.00	0/15.00	0/14.39	0/13.53
POLY-3 PERCENT (g)	14.3%	7.0%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	1/12 (8%)	1/14 (7%)	0/15 (0%)	0/15 (0%)	0/12 (0%)	0/10 (0%)
FIRST INCIDENCE	145	185 (T)	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	P=0.146N	P=0.464N	P=0.208N	P=0.208N	P=0.232N	P=0.260N
POLY 3	P=0.133N	P=0.490N	P=0.215N	P=0.215N	P=0.224N	P=0.238N
POLY 1.5	P=0.132N	P=0.495N	P=0.221N	P=0.221N	P=0.226N	P=0.234N
POLY 6	P=0.135N	P=0.484N	P=0.207N	P=0.207N	P=0.222N	P=0.245N
LOGISTIC REGRESSION	P=0.139N	P=0.542N	P=0.416N	P=0.416N	P=0.347N	P=0.252N
COCH-ARM / FISHERS	P=0.131N	P=0.500N	P=0.241N	P=0.241N	P=0.241N	P=0.241N

Females

Dose	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
Lung Alveolar/Bronchiolar Adenoma						
TUMOR RATES						
OVERALL (a)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)	0/15 (0%)
POLY-3 RATE (b)	0/12.95	0/14.05	0/12.72	0/14.49	0/14.03	0/10.72
POLY-3 PERCENT (g)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
TERMINAL (d)	0/12 (0%)	0/14 (0%)	0/12 (0%)	0/12 (0%)	0/13 (0%)	0/9 (0%)
FIRST INCIDENCE	---	---	---	---	---	---
STATISTICAL TESTS						
LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)

Males

Dose	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
Skin Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom						
TUMOR RATES	#	#	#	#	#	#
OVERALL (a)	1/15 (7%)	0/15 (0%)	4/15 (27%)	15/15 (100%)	15/15 (100%)	13/15 (87%)
POLY-3 RATE (b)	1/13.43	0/14.34	4/15.00	15/15.00	15/15.00	13/15.00
POLY-3 PERCENT (g)	7.4%	0.0%	26.7%	100.0%	100.0%	86.7%
TERMINAL (d)	1/12 (8%)	0/14 (0%)	4/15 (27%)	15/15 (100%)	12/12 (100%)	8/10 (80%)
FIRST INCIDENCE	185 (T)	---	185 (T)	185 (T)	163	138
STATISTICAL TESTS						
LIFE TABLE	P<0.001 **	P=0.469N	P=0.240	P<0.001 **	P<0.001 **	P<0.001 **
POLY 3	P<0.001 **	P=0.487N	P=0.198	P<0.001 **	P<0.001 **	P<0.001 **
POLY 1.5	P<0.001 **	P=0.493N	P=0.183	P<0.001 **	P<0.001 **	P<0.001 **
POLY 6	P<0.001 **	P=0.479N	P=0.218	P<0.001 **	P<0.001 **	P<0.001 **
LOGISTIC REGRESSION	P<0.001 **	(e)	P=0.240	P<0.001 **	P<0.001 **	P<0.001 **
COCH-ARM / FISHERS	P<0.001 **	P=0.500N	P=0.165	P<0.001 **	P<0.001 **	P<0.001 **

Females

Dose	0 MG/KG	0.75 MG/KG	1.5 MG/KG	3 MG/KG	6 MG/KG	12 MG/KG
Skin Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepitheliom						
TUMOR RATES	#	#	#	#	#	#
OVERALL (a)	0/15 (0%)	0/15 (0%)	1/15 (7%)	10/15 (67%)	12/15 (80%)	13/15 (87%)
POLY-3 RATE (b)	0/12.95	0/14.05	1/12.72	10/14.63	12/14.10	13/14.00
POLY-3 PERCENT (g)	0.0%	0.0%	7.9%	68.4%	85.1%	92.8%
TERMINAL (d)	0/12 (0%)	0/14 (0%)	1/12 (8%)	9/12 (75%)	11/13 (85%)	8/9 (89%)
FIRST INCIDENCE	---	---	186 (T)	177	182	98
STATISTICAL TESTS						
LIFE TABLE	P<0.001 **	(e)	P=0.500	P<0.001 **	P<0.001 **	P<0.001 **
POLY 3	P<0.001 **	(e)	P=0.496	P<0.001 **	P<0.001 **	P<0.001 **
POLY 1.5	P<0.001 **	(e)	P=0.497	P<0.001 **	P<0.001 **	P<0.001 **
POLY 6	P<0.001 **	(e)	P=0.493	P<0.001 **	P<0.001 **	P<0.001 **
LOGISTIC REGRESSION	P<0.001 **	(e)	P=0.500	P<0.001 **	P<0.001 **	P<0.001 **
COCH-ARM / FISHERS	P<0.001 **	(e)	P=0.500	P<0.001 **	P<0.001 **	P<0.001 **